Here's Why Summit Therapeutics Stock Price Rose 6% on Friday [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
development, with its competitors at least a couple of years away from reaching the same clinical development position. Ivonescimab is currently approved in China for the treatment of patients with EGFR mutated, locally advanced or metastatic non-squamous NSCLC, and Summit is conducting two late-stage studies on the drug in separate NSCLC settings, with data from one study expected in mid-2025 and potential FDA approval in 2026. Jefferies expects ivonescimab to generate nearly $10 billion in peak sales in the NSCLC indication alone, based on the results of the phase III HARMONi-2 study. Ivonescimab is a first-in-class bispecific antibody that targets two proteins, PD-1 and VEGF, and has shown statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Keytruda in patients with non-small cell lung cancer (NSCLC). Summit Therapeutics' stock price rose 6% on Friday after analysts at Jefferies initiated coverage on the company wit
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Where Will Summit Therapeutics Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- 3 Stocks That Could Turn $1,000 into $5,000 by 2030 [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
SMMT
Earnings
- 10/30/24 - Beat
SMMT
Sec Filings
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- SMMT's page on the SEC website